Slide 1: Orion Full-Year 2024 Result presentation
Orion Full-Year 2024 Result presentation 25 February 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Some highlights from news flow in 2024 and early 2025
Some highlights from news flow in 2024 and early 2025 • Refined strategy and financial targets New R&D collaborations • Orion and MSD collaboration agreement converted to global Becomes a blockbuster exclusive license to MSD • Positive read-out from Phase III Corporate responsibility ARANOTE trial •
Slide 4: Q4 2024 – Very strong sales growth in all fronts
Q4 2024 – Very strong sales growth in all fronts • Four of five business divisions showed strong 10–12/ 10–12/ growth 2024 2023 Change • Nubeqa®again the leading growth driver but many other products also recorded very good growth Net sales, EUR million 434.4 321.1 +35.3% • Operating profit was at s
Slide 5: Full-Year 2024 results
Full-Year 2024 results • Nubeqa® and two significant milestone payments, 1–12/ 1–12/ in total EUR 130 million, driving the growth Change 2024 2023 • Branded Products, Generics and Consumer Health, and Animal Health business divisions also Net sales, EUR million 1,542.4 1,189.7 +29.6% developed favou
Slide 6: Underlying net sales and operating profit showing strong growth
Underlying net sales and operating profit showing strong growth Net sales, EUR million Operating profit, EUR million 1,542.4 416.6 3.4 130.0 1,189.7 130.0 30.0 274.9 30.7 30.0 1,412.4 1,159.7 283.2 214.2 2023 2024 2023 2024 Major milestones Pension fund items Underlying net sales Major milestones Un
Slide 7: Year back-end loaded – mainly due to Nubeqa royalty structure
Year back-end loaded – mainly due to Nubeqa® royalty structure Net sales, EUR million Operating profit, EUR million 471.3 202.0 434.4 3.4 130.0 35.8 328.2 116.2 308.5 20.8 26.4 17.8 130.0 31.7 50.8 68.7 92.7 65.8 282.4 56.0 259.0 256.6 246.2 68.6 Q1’2024 Q2’2024 Q3’2024 Q4’2024 Q1’2024 Q2’2024 Q3’20
Slide 8: Net sales bridge (MEUR)
Net sales bridge (MEUR) 101.4 3.9 1,542.4 22.9 32.4 22.2 185.8 -4.3 1,189.7 -11.6 1–12/2023 1 2 3 4 5 6 7 8 1–12/2024 1 Simdax® and dexmedetomidine for human use 5 Other products and services (excl. Animal Health and Fermion) 2 Nubeqa® (product sales and royalty) 6 Animal Health and Fermion 3 Entaca
Slide 9: Operating profit bridge (MEUR)
Operating profit bridge (MEUR) -6.9 EUR -41.0 million write 101.4 -112.9 downs included -27.3 416.6 147.1 -31.6 68.8 3.1 274.9 1–12/2023 1 2 3 4 5 6 7 8 1–12/2024 1 Product & service sales without sales margin and product mix change and exchange rate effect 5 Milestones 2 Product sales margin and pr
Slide 10: Innovative Medicines
Innovative Medicines +123.4% Nubeqa® sales (MEUR) 525.2 152 60.0 • Underlying business (Nubeqa®) 36 showed very strong growth 70.0 26.9 • Due to the Nubeqa® royalty 95 structure, sales accelerated MEUR 72 26 towards the end of the year 235.1 62 30.0 21 116 • Ganaxolone contract with 22.6 368.3 45 50
Slide 11: Branded Products
Branded Products +10.2% • Easyhaler® product portfolio 287.4 Sales split 260.9 12.7 (+15.4%) continued strong 7.3 24.2 growth with budesonide- 4% 21.0 8% formoterol combination product 84.1 (+22.3%) as a driver 88.4 • Sales volume of the entacapone MEUR products increased but due to 29% declining pr
Slide 12: Generics and Consumer Health
Generics and Consumer Health +2.1% Sales split by geographic areas • H2 and especially Q4 were 517.6 528.4 strong 13% • All key markets performing well 130.9 132.1 9% MEUR 396.3 17% 61% 386.7 1–12/2023 1–12/2024 Generic prescription drugs Finland and Baltics Eastern Europe Self-care products Scandin
Slide 13: Animal Health and Fermion
Animal Health and Fermion Animal Health Fermion • Animal Health recovering from weak 2023 +23.4% • Animal Health growth came 128.2 from various sources with animal sedatives being the single 103.9 31.9 largest contributor 22.8 -1.8% • Fermion’s capacity allocated MEUR 73.7 72.3 more to internal use
Slide 14: TOP 10 products and total sales split by division
TOP 10 products and total sales split by division EUR vs. Product or product portfolio million 1–12/2023 1. Nubeqa® 368.3 >100% 5% 8% 2. Easyhaler® product portfolio 166.4 +15.4% 3. Entacapone products1 84.1 -4.8% 34% 4. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 31.9 +40.4% 5. Burana® 24.6 -2.0%
Slide 15: Key clinical development pipeline
Key clinical development pipeline Partner Project/compound Indication PHASE I PHASE II PHASE III REGISTRATION ARANOTE / darolutamide Prostate cancer (mHSPC) Ongoing ARASTEP / darolutamide Prostate cancer (BCR) OMAHA1 / opevesostat Prostate cancer (mCRPC) OMAHA2a / opevesostat Prostate cancer (mCRPC)
Slide 16: Board report, financial statements and sustainability statement publication
The report of the Board of Directors, Financial Statements, Sustainability Statement, Corporate Governance Statement and Remuneration Report for 2024 to be published at the latest in week 11/2025. 16
Slide 17: Outlook for 2025
Outlook for 2025 Net sales EUR 1,550–1,650 million Operating profit EUR 350–450 million 17 25 February 2025 © Orion Corporation
Slide 18: Underlying net sales and operating profit estimated to show strong growth
Underlying net sales and operating profit estimated to show strong growth Net sales, EUR million Operating profit, EUR million 1,650 450 417 • Nubeqa® most significant 3 1,542 variable in net sales range 130 • Nubeqa®, timing of R&D costs 130 and USD Fx most significant variables in operating profit
Slide 19: Save the Date: Capital Markets Day in Helsinki
Save the Date: Capital Markets Day in Helsinki on 22 May 2025
Slide 20: Upcoming events
Upcoming events AGM 2025 planned to be held 3/4/2025 Interim Report 1–3/2025 23/4/2025 Capital Markets Day 22/5/2025 Half-Year Financial Report 1–6/2025 18/7/2025 Interim Report 1–9/2025 28/10/2025 20 25 February 2025 © Orion Corporation